Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone versus Glorenta in adults with non-alcoholic fatty liver disease and type 2 diabetes
IRCT20250919067293N1Phase 4Completed
- Sponsor
- Baqiyatallah University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of pioglitazone in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Baqiyatallah University of Medical Sciences. Primary endpoints: Lipid profile, Body mass index and 8 more. Started Oct 2025; status: completed.
02
Drugs
pioglitazone
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20250919067293N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250919067293N1.